Access cutting-edge ulcerative colitis treatment through this clinical trial at a research site in Dothan. Study-provided care at no cost to qualified participants.
Access ulcerative colitis specialists in Dothan at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ulcerative colitis treatment provided free
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Sponsor: Eli Lilly and Company
Check if you qualify for this ulcerative colitis clinical trial in Dothan, AL
If you're searching for ulcerative colitis treatment options in Dothan, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Dothan research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ulcerative colitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.